The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the diabetes control and complications trial

Diabetes

Volumn 56, Issue 7, 2007, Pages 1913-1921

  Lachin, John M ^a,d   Genuth, Saul ^b   Nathan, David M ^c   Rutledge, Brandy N ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d George Washington University Biostatistics Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; ANALYTIC METHOD; ARTICLE; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN GLYCATION INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HEALTH STATUS INDICATORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MICROCIRCULATION; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 34347406488     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db07-0028     Document Type: Article

References (23)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
3. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996
4. McCarter MJ, Gomez R, Hempe JM, Chalew SA: Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 27:1259-1264, 2004
5. Hempe JM, Gomez R, McCarter RJ, Chalew SA: High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications 16:313-320, 2002
6. Genuth S, Nathan DM, Lachin JM: Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to McCarter et al. Diabetes Care 28:233; author reply 234-235, 2005
7. Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology 98 (Suppl.): 823-833, 1991
8. Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. New York, Oxford University Press, 1994
9. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, John Wiley & Sons, 1980
10. Chalew SA, Hempe JM, McCarter MJ: Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes: response to Genuth, Lachin, and Nathan. Diabetes Care 28:234-235, 2005
11. Cohen RM, Holmes YR, Chenier TC, Joiner CH: Discordance between hemoglobin A1c and fructosamine: evidence for a glycosylation gap and its relation to nephropathy in longstanding type 1 diabetes. Diabetes Care 26:163-167, 2003
12. Delpierre G, Collard F, Fortpied J, Van Schaftingen E: Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes. Biochem J 365:801-808, 2002
13. Szwergold BS, Beisswenger PJ: Enzymatic deglycation: a new paradigm or an epiphenomenon? Biochem Soc Trans 31:1428-1432, 2003
14. Svendsen PA, Lauritzen T, Soegaard U, Nerup J: Glycosylated hemoglobin and steady state mena blood glucose concentrations in type 1 (insulin-dependent) diabetes. Diabetologia 23:403-405, 1982
15. Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 310:341-346, 1984
16. Gould BJ, Davie, Yudkin JS: Investigation of the mechanism underlying the variability of glycated hemoglobin in nondiabetic subjects not related to glycemia. Clin Chem Acta 260:49-64, 1997
17. Virtue MA, Furne JK, Nuttal FQ, Levitt MD: Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 27:931-935, 2004
18. Snieder H, Sawtell PA, Ross L, Walker J, Spector TD, Leslie RDG: HbA1c levels are genetically determined even in type 1 diabetes. Diabetes 50:2858-2863, 2001
19. Service FJ, O'Brien PC: The relation of glycemia to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetologia 44:1215-1220, 2001
20. Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486-1490, 2006
21. Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Int Med 251:87-101, 2002
22. Monnier VM, Bautista O, Kenny D, et al.: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type I diabetes. Diabetes 48:870-880, 1999
23. Genuth SM, Sun W, Cleary P, et al.: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54:3103-3111, 2005